Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more
Can Fite Biopharma Ltd (CANF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.568x
Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.38 Million) by net assets (ILA4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Can Fite Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Can Fite Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Can Fite Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Can Fite Biopharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuchai Develop Bhd
KLSE:2186
|
-0.008x |
|
CF Acquisition Corp. VII Warrant
NASDAQ:CFFSW
|
N/A |
|
SOLARHYBRID
BE:SHC
|
N/A |
|
CUSHMAN WAKEF. DL01
F:2IY
|
N/A |
|
WUESTENROT & WUERTT
BE:WUW
|
N/A |
|
Nykredit Invest - Kreditobligationer
CO:NYIKRO
|
N/A |
|
GUESS? (GU9.SG)
STU:GU9
|
0.084x |
|
Picpay Holdings Netherlands N.V. Class A Common Shares
NASDAQ:PICS
|
0.453x |
Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA5.44 Million | ILA-7.64 Million | -1.405x | -3.92% |
| 2023-12-31 | ILA6.24 Million | ILA-8.44 Million | -1.352x | +44.03% |
| 2022-12-31 | ILA4.47 Million | ILA-10.80 Million | -2.415x | -252.36% |
| 2021-12-31 | ILA14.38 Million | ILA-9.86 Million | -0.685x | +65.49% |
| 2020-12-31 | ILA6.07 Million | ILA-12.06 Million | -1.986x | +55.24% |
| 2019-12-31 | ILA2.44 Million | ILA-10.83 Million | -4.437x | -221.93% |
| 2018-12-31 | ILA3.02 Million | ILA-4.16 Million | -1.378x | +55.81% |
| 2017-12-31 | ILA3.05 Million | ILA-9.52 Million | -3.118x | -35.33% |
| 2016-12-31 | ILA3.87 Million | ILA-8.93 Million | -2.304x | -417.41% |
| 2015-12-31 | ILA10.44 Million | ILA-4.65 Million | -0.445x | +58.32% |
| 2014-12-31 | ILA6.86 Million | ILA-7.33 Million | -1.069x | +44.80% |
| 2013-12-31 | ILA4.46 Million | ILA-8.63 Million | -1.936x | -131.52% |
| 2012-12-31 | ILA-707.99K | ILA-4.35 Million | 6.141x | +467.80% |
| 2011-12-31 | ILA3.29 Million | ILA-5.50 Million | -1.670x | -497.22% |
| 2010-12-31 | ILA13.07 Million | ILA-3.65 Million | -0.280x | -- |